Akshat Jain: Marstacimab Gets FDA Expension for Children with Hemophilia B
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn:
”Major FDA Milestone for Hemophilia Care: Marstacimab Label Expansion especially Children under 12yrs with Hemophilia B suffering from Inhibitors!
The U.S. FDA has approved an expanded indication for marstacimab, extending its use to:
- Patients with hemophilia A or B aged 12 years and older with inhibitors
- Children aged 6–11 years with hemophilia A or B, with or without inhibitors.
This approval makes HYMPAVZI the first subcutaneous non-factor therapy available for pediatric patients with hemophilia B aged 6–11 years, addressing a longstanding unmet need in the bleeding disorders community.
As a pediatric hematologist, I view this as a particularly important advancement for Hemophilia B families that suffer from inhibitors who have since long being searching for an optimal way to manage bleeding in the setting of high titer inhibitors!
Historically, young patients with inhibitors have faced limited treatment options, significant treatment burden, and challenges maintaining consistent bleed protection.
A once-weekly subcutaneous anti-TFPI therapy offers a meaningful alternative to frequent intravenous infusions while expanding access to effective prophylaxis for a population that has long been underserved.
The approval is supported by data from the Phase 3 BASIS study, which demonstrated a 93% reduction in treated annualized bleeding rates compared with on-demand bypassing therapy in patients with inhibitors.
This milestone reflects the continued evolution of hemophilia care beyond factor replacement, bringing us closer to a future where treatment is more convenient, effective, and patient-centered—especially for children and families navigating the daily challenges of hemophilia.
Hopefully these therapies will be available for the children under 6 yrs suffering from sometimes worse bleeding in early childhood from falls,trauma and sports , very soon.”

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome